Research Papers

21 of 21 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
The impact of proton LET/RBE modeling and robustness analysis on base-of-skull and pediatric craniopharyngioma proton p…
Gutierrez A; Rompokos V; Li K; Gillies C; D'Souza D; Solda F; Fersht N; Chang YC; Royle G; Amos RA; Underwood T.
Acta Oncol (Unknown)
Published: 2019
2/6 Transparent
Funding Declared
A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy.
Jochems A; El-Naqa I; Kessler M; Mayo CS; Jolly S; Matuszak M; Faivre-Finn C; Price G; Holloway L; Vinod S; Field M; Barakat MS; Thwaites D; de Ruysscher D; Dekker A; Lambin P.
Acta Oncol (Unknown)
Published: 2017
2/6 Transparent
Funding Declared
A modeling study of functional magnetic resonance imaging to individualize target definition of seminal vesicles for ex…
Damkjær S; Thomsen JB; Petersen SI; Bangsgaard JP; M Petersen P; Vogelius IR; Aznar MC.
Acta Oncol (Unknown)
Published: 2017
2/6 Transparent
Funding Declared
The accuracy of preoperative axillary nodal staging in primary breast cancer by ultrasound is modified by nodal metasta…
Dihge L; Grabau DA; Rasmussen RW; Bendahl PO; Rydén L.
Acta Oncol (Unknown)
Published: 2016
2/6 Transparent
Funding Declared
Testing the methodology for dosimetry audit of heterogeneity corrections and small MLC-shaped fields: Results of IAEA m…
Izewska J; Wesolowska P; Azangwe G; Followill DS; Thwaites DI; Arib M; Stefanic A; Viegas C; Suming L; Ekendahl D; Bulski W; Georg D.
Acta Oncol (Unknown)
Published: 2016
1/6 Transparent
Funding Declared
A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell c…
Soerensen AV; Geertsen PF; Christensen IJ; Hermann GG; Jensen NV; Fode K; Petersen A; Sandin R; Donskov F.
Acta Oncol (Unknown)
Published: 2015
3/6 Transparent
Registered Funding Declared
Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pan…
Elebro J; Ben Dror L; Heby M; Nodin B; Jirström K; Eberhard J.
Acta Oncol (Unknown)
Published: 2015
2/6 Transparent
Funding Declared
The role of personality in the course of health-related quality of life and disease-specific health status among colore…
Husson O; Vissers PA; Denollet J; Mols F.
Acta Oncol (Unknown)
Published: 2015
2/6 Transparent
Funding Declared
Breast cancer specialists' views on and use of risk prediction models in clinical practice: a mixed methods approach.
Engelhardt EG; Pieterse AH; van Duijn-Bakker N; Kroep JR; de Haes HC; Smets EM; Stiggelbout AM.
Acta Oncol (Unknown)
Published: 2014
1/6 Transparent
LRIG and cancer prognosis.
Lindquist D; Kvarnbrink S; Henriksson R; Hedman H.
Acta Oncol (Unknown)
Published: 2014
1/6 Transparent
Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma.
Berner K; Johannesen TB; Berner A; Haugland HK; Bjerkehagen B; Bøhler PJ; Bruland ØS.
Acta Oncol (Unknown)
Published: 2014
2/6 Transparent
Funding Declared
No clinically relevant effect on cognitive outcomes after low-dose radiation to the infant brain: a population-based co…
Blomstrand M; Holmberg E; Aberg MA; Lundell M; Björk-Eriksson T; Karlsson P; Blomgren K.
Acta Oncol (Unknown)
Published: 2014
2/6 Transparent
Funding Declared
Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capeci…
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Saarni O; Helle L; Villman K; Nyandoto P; Nilsson G; Leinonen M; Kataja V; Bono P; Lindman H.
Acta Oncol (Unknown)
Published: 2013
3/6 Transparent
Registered Funding Declared
Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associat…
Kil WJ; Nichols RC; Hoppe BS; Morris CG; Marcus RB; Mendenhall W; Mendenhall NP; Li Z; Costa JA; Williams CR; Henderson RH.
Acta Oncol (Unknown)
Published: 2013
1/6 Transparent
Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer…
Henderson RH; Hoppe BS; Marcus RB; Mendenhall WM; Nichols RC; Li Z; Su Z; Morris CG; Williams CR; Costa J; Mendenhall NP.
Acta Oncol (Unknown)
Published: 2013
1/6 Transparent
Population-based study on use of chemotherapy in men with castration resistant prostate cancer.
Lissbrant IF; Garmo H; Widmark A; Stattin P.
Acta Oncol (Unknown)
Published: 2013
3/6 Transparent
Registered Funding Declared
The crosstalk: Tumor-infiltrating lymphocytes rich in regulatory T cells suppressed cancer-associated fibroblasts.
Fu Z; Zuo Y; Li D; Xu W; Li D; Chen H; Zheng S.
Acta Oncol (Unknown)
Published: 2013
2/6 Transparent
Funding Declared
Weight loss in patients with head and neck cancer during and after conventional and accelerated radiotherapy.
Ottosson S; Zackrisson B; Kjellén E; Nilsson P; Laurell G.
Acta Oncol (Unknown)
Published: 2012
2/6 Transparent
Funding Declared
Quality assessment of the registration of vulvar and vaginal premalignant lesions at the Cancer Registry of Norway.
Enerly E; Bray F; Mellem C; Hansen BT; Kjølberg G; Dahl T; Johannesen TB; Nygård M.
Acta Oncol (Unknown)
Published: 2011
1/6 Transparent
Is genetic counseling a stressful event?
Nordin K; Roshanai A; Bjorvatn C; Wollf K; Mikkelsen EM; Bjelland I; Kvale G.
Acta Oncol (Unknown)
Published: 2011
2/6 Transparent
Funding Declared
Management of cutaneous metastases using electrochemotherapy.
Matthiessen LW; Chalmers RL; Sainsbury DC; Veeramani S; Kessell G; Humphreys AC; Bond JE; Muir T; Gehl J.
Acta Oncol (Unknown)
Published: 2011
2/6 Transparent
Funding Declared